Related Experiment Videos
Uremic bleeding: pathogenesis and therapy
1Hospital de Santa Cruz and Faculdade de Medicina de Universidade Classica de Lisboa, Lisbon, Portugal.
The American Journal of the Medical Sciences
|August 15, 1998
Summary
Uremic bleeding is complex, but bleeding time is a key indicator. Dialysis and erythropoietin are improving management of this bleeding risk in kidney disease patients.
Area of Science:
- Nephrology
- Hematology
- Internal Medicine
Background:
- Uremic bleeding diathesis presents significant clinical challenges.
- Understanding its pathophysiology is crucial for effective patient management.
Purpose of the Study:
- To review the pathophysiology of uremic bleeding.
- To discuss current therapeutic interventions for bleeding risk in uremic patients.
Main Methods:
- Comprehensive literature search of existing research and reviews.
- Analysis of studies on uremic bleeding pathophysiology and clinical management.
Main Results:
- Common bleeding includes prolonged oozing, epistaxis, GI/GU bleeding, and subdural hematomas.
- Bleeding time is the most reliable test for assessing bleeding risk and treatment response.
- Anemia, assessed by hematocrit, significantly impacts bleeding risk; correction via transfusions or erythropoietin is vital.
- Dialysis improves hemostasis; renal transplantation resolves it.
- Desmopressin acetate and conjugated estrogens are key therapeutic agents, each with distinct onset and duration profiles.
Conclusions:
- The pathophysiology of uremic bleeding is complex and not fully elucidated.
- Empirically developed clinical tests and therapies have proven useful.
- Widespread dialysis and erythropoietin are expected to decrease the incidence and severity of uremic bleeding.